Intellia Therapeutics (NTLA) stock

Gene-editing medicines , market cap $1.6B

Gene-editing medicines

Worth $1.6B

$11.17

-7.76%

As of Tuesday's close · Live for Pro members at the open

Why is NTLA down?

Down 7.8% today, more than its biotech peers' 1.4%; no story names it yet.

Fell on Nov 5

Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

“The decrease is primarily due to a reduction in revenue from Regeneron.”

Intellia Therapeutics' Nov 5 release said

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

Tell me next time NTLA moves

Free account, no card. An optional alert when NTLA moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →3 more reasons why NTLA fell on Nov 5, from its filings, with the other side, how the business stands, the company's words, the timeline, and its peers, for Pro members.

Quality Score

-7

Poor

In its industry

#245of 281

Biotech

Checks firing

1of 14

Choppy

From 52-week high

-39.6%

under its best in a year

Down:Lowest Quality Score since Jul 2025. Scores before Sep 10, 2026 were rebuilt.

NTLA's Quality Score fell 1 point on Tue, Nov 10, to -7. It closed away from its high of the day (2 chart checks stopped).

Follow NTLA's trial news. Pro members can get an alert when Intellia Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NTLA files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027”Filing with regulators · SEC filing · Aug 6

Cash$615M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into 2028”

Key facts on NTLA

Key facts on NTLA
Since its Nov 2021 high	Down 91% a $267.9M loss → a $426.1M loss
Its score	Down:Lowest Quality Score since Jul 2025 Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind NTLA's -7, free with an account →4 more reasons behind NTLA's -7, for Pro members.

NTLA in the news

TodayNo story names it yet.

What's next

Expected to report Thu Feb 25, before the open

After its last 4 reports it closed +0.3% on average, higher 3 of 4 times.

Cash$615M, about 6 quarters at the last year's spendingOn Sep 30 · the company says “into 2028”

NTLA catalysts

Coming up

4 more coming up and 11 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for NTLA, and how long its cash lasts

Next step the company has named

2H 2026“Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027”Filing with regulators · SEC filing · Aug 6

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: NTLA-2001 in ATTRv-PNPhase 3 · Active · 67 people · main data estimated Jul 2027 · NCT06672237

3 more trials, 3 more milestones and 44 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 6 quarters

$615M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2028” (8-K, Nov 5).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 24, 2023)
At-the-market share sales program (424B5, filed Feb 26, 2024)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO John M. Leonard sold 9,000 shares on Nov 2, under a planned sale. 15 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when John Leonard buys or sells

For Pro members: every trade, and John Leonard’s 14 filings and quotes.

Get an alert when NTLA files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why NTLA scores -7

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

-7 is below -5, off the left end of the scale.

−2Long-term trend below a falling 200-⁠day average, down over two years
−2Dilution 27.2% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Chart checks adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News subtracts

No effect today: Run-up, Size, Growth, Persistence, and Insider trades.

What every line is worth, and the reason behind it, on NTLA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How NTLA ranks in Biotech

NTLA is #245 of 281 by Quality Score.

How NTLA ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	NRIXNurix Therapeutics		Open for its score
	NRXPNRX Pharmaceuticals		Open for its score
	NUVBNuvation Bio		Open for its score
	NVAXNovavax		Open for its score
245	NTLAIntellia Therapeutics	1/14	-7

Share count against a year before: NTLA +27%, EDIT +70%, BEAM +2.1%, CRSP +6%.

When does NTLA report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NTLA reported on Nov 5, 2026

The quarter

A loss of $0.91 a share, from $0.92.

“The decrease is primarily due to a reduction in revenue from Regeneron.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

NTLA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Net loss for the third quarters of 2026 and 2025 included an unrealized loss of $10.4 million and an unrealized gain of $3.4 million, respectively, due to changes in the fair value of investments.”

From its results filing (SEC filing · Nov 5)

2 more sentences, for Pro members.

The numbers

Market value: $1.6B; today
Sales: $52.9M; down 8.1% on the year
Free cash flow: -$358M; last 12 months

Sales grew 3.1% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 14% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NTLA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+2.3%+2.5%-9.8%

May 11Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	-0.4%	-9.8%	not yet
Aug 6, 2026Before open	Before open	-3.0%	+2.5%	+10.2%
May 11, 2026Before open	Before open	-0.2%	+2.3%	-3.0%

NTLA closed higher after 3 of its last 4 reports.

All 4 reports, and NTLA's Quality Score going into each

NTLA sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $67.7M in 2025. It lost money in each of the eight years.

NTLA has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NTLA, and all 14 on every stock.Get in free →

NTLA RSI today: 44.5, below its 50-day and 200-day averages

Not scored

RSI 44.5, MACD below signal, below both averages. Not scored.13 readings

The deep dive on NTLA

What it does and how it makes money3 findingsAn operating loss of $441M in fiscal 2025, on $67.7M of sales.Annual report, filed Feb 26, 2026"Under the 2016 Regeneron Agreement, we will be eligible to receive up to $320.0 million per in vivo target in development and commercial milestone payments, as well as up to mid-single-digit royalties on potential future sales." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands2 findingsFor Pro members2 findings on where NTLA stands: its cash, debt, and share count, for Pro members
What changed in its filings1 finding"On September 12, 2024, we filed a motion to dismiss the complaint, and on December 9, 2024, the court denied the motion to dismiss and discovery began." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades NTLA, for Pro members
Against its closest peers3 peersShare count against a year before: NTLA +27%, EDIT +70%, BEAM +2.1%, CRSP +6%.

5 more findings on NTLA, each with its source, for Pro members.

NTLA share count over time

27% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of NTLA outstanding, as filed
Shares outstanding	As of
140.4M	Oct 30, 2026
140.1M	Jul 31, 2026
139.7M	Apr 30, 2026
118.1M	Feb 13, 2026

Offerings, shelves, and splits of NTLA, from its filings
From its filings	Filed
Raised $180M in a sale of shares, about 12% of its market value	Apr 29, 2026
Set up an at-the-market program for up to $375.7M of shares, about 24% of its market value	Feb 26, 2024
Set up an at-the-market program for up to $375.7M of shares, about 24% of its market value	Feb 23, 2024
Registered shares for a later sale (S-3ASR)	Nov 24, 2023

NTLA insider trades

2 insiders sold $159K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellMichael P. Dube$23KVP, Chief Accounting Officerat $12.43 on Oct 2, filed Oct 6

SellMichael P. DubeVP, Chief Accounting Officer$23Kat $12.43 on Oct 2, filed Oct 6

All 3 insider filings on NTLA from the last six months, for Pro members.

All NTLA insider trades

NTLA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

John M. LeonardPresident and CEO · 5 trades
Edward J. Dulac IIIEVP, Chief Financial Officer · 3 trades
Michael P. DubeVP, Chief Accounting Officer · 3 trades
Eliana ClarkEVP, Chief Technical Officer · 2 trades
James BastaEVP, General Counsel · 2 trades
Birgit C. SchultesEVP, Chief Scientific Officer · 1 trade
David LebwohlEVP, Chief Medical Officer · 1 trade
Jing L. MarantzEVP, Chief Medical Officer · no trades on file

7 more officers and directors file at NTLA.

See insider trades by person

Which ETFs hold NTLA?

In ETFs: NTLA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

377 employeesCambridge, MAintelliatx.com

What Intellia Therapeutics says it competes with

“The biotechnology and pharmaceutical industries are extremely competitive in the race to develop new products.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NTLA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn NTLA's score around: 9 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 6Michael P. Dube sold NTLA$23K at $12.43, filed Oct 6

Alerts are optional.

See NTLA's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: NTLA's Quality Score is -7 (Poor), #245 of 281 in Biotech. Insiders sold $159K in the last 6 months (Form 4).

What does NTLA's Quality Score say?

NTLA scores -7 today, which Breakaway calls Poor. It is #245 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NTLA's Quality Score?

NTLA scores -7 today, which Breakaway calls Poor (below zero). That is #245 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NTLA's -7.

Are insiders buying NTLA?

2 insiders sold $159K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Michael P. Dube, VP, Chief Accounting Officer, who sold $23K on Oct 2. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.